Clinical Trial

Phase I Study of HRS-1635 in B-cell Malignancies

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The study is being conducted to evaluate the safety and tolerability of HRS-1635. To observe the Dose-Limiting Toxicity (DLT) , explore the Maximum Tolerated Dose (MTD, if possible) and the Recommended Phase 2 Dose (RP2D). This study also preliminarily evaluated the efficacy of HRS-1635 in participants with B-cell malignancy.
Protocol Amendment History 1 change
critical Recruitment opened 2026-07-14
Trial Details
NCT Number NCT07583212
Lead Sponsor Chengdu Suncadia Medicine Co., Ltd.
Conditions B-cell Malignancy
Enrollment 180 participants
Start Date 2026-06-30
Primary Completion 2028-10 (estimated)
Study Completion 2029-12 (estimated)
Updated on ClinicalTrials.gov 2026-07-13